Last reviewed · How we verify
Vonoprazan + amoxicillin
Vonoprazan inhibits gastric acid secretion while amoxicillin kills Helicobacter pylori bacteria, together eradicating H. pylori infection.
Vonoprazan inhibits gastric acid secretion while amoxicillin kills Helicobacter pylori bacteria, together eradicating H. pylori infection. Used for Helicobacter pylori eradication in peptic ulcer disease, H. pylori-associated gastritis.
At a glance
| Generic name | Vonoprazan + amoxicillin |
|---|---|
| Sponsor | The Third Xiangya Hospital of Central South University |
| Drug class | Potassium-competitive acid blocker (PCAB) + beta-lactam antibiotic combination |
| Target | H+/K+-ATPase (vonoprazan); bacterial cell wall peptidoglycan (amoxicillin) |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Vonoprazan is a potassium-competitive acid blocker (PCAB) that suppresses gastric acid production by inhibiting the H+/K+-ATPase pump, creating an environment hostile to acid-dependent pathogens. Amoxicillin is a beta-lactam antibiotic that disrupts bacterial cell wall synthesis. Together, this combination therapy is used for H. pylori eradication, typically as part of a triple or quadruple regimen.
Approved indications
- Helicobacter pylori eradication in peptic ulcer disease
- H. pylori-associated gastritis
Common side effects
- Diarrhea
- Nausea
- Abdominal discomfort
- Headache
- Allergic reaction (amoxicillin)
Key clinical trials
- Efficacy and Safety of 14-Day Vonoprazan-Based Dual Therapy Versus Quadruple Therapy for Helicobacter Pylori Eradication: A Multicentre, Non-Inferiority Randomized Controlled Trial (NA)
- Dual Therapy With Vonoprazan Plus Amoxicillin or Doxycycline Versus Bismuth Quadruple Therapy for Helicobacter Pylori Eradication. (NA)
- Banxiaxiexin Decoction Combined With Vonoprazan-Amoxicillin Dual Therapy in H. Pylori Eradication (PHASE3)
- Helicobacter Pylori Screening and Treatment in the At-risk South Florida Community- AIM 1 (PHASE4)
- Fourteen-Day Vonoprazan-Based Dual Therapy With Amoxicillin as First-Line Helicobacter Pylori Treatment in Comparison With Extended Sequential Therapy (PHASE4)
- Vonoprazan vs Proton Pump Inhibitor With Vitamin D or Probiotics Based Triple Therapy for Eradication of Helicobacter Pylori Infection (PHASE2)
- Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy and Bismuth Quadruple Therapy (NA)
- 7-day High-Dose Vonoprazan-amoxicillin Dual Therapy Versus 14-day Vonoprazan-amoxicillin Dual Therapy for H. Pylori (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |